Form 4: Cryoport Director Daniel Hancock Receives Significant Equity Awards

Cryoport, Inc. Director Daniel M. Hancock was granted 23,214 restricted stock rights and 41,098 stock options, increasing his beneficial ownership and aligning his interests with the company's long-term performance.

Summary

• Daniel M. Hancock, a Director of Cryoport, Inc. (CYRX), reported equity awards granted on June 6, 2025.
• He was granted 23,214 restricted stock rights, which are scheduled to vest in full on June 6, 2026, and will convert into common stock on a one-for-one basis upon vesting.
• Following this transaction, Mr. Hancock's direct beneficial ownership of common stock is 58,702 shares.
• Additionally, he received 41,098 options to purchase common stock at an exercise price of $7 per share.
• These options will vest monthly at a rate of 1/12th, commencing July 6, 2025, and are set to expire on June 6, 2032.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal, indicating alignment of interests and retention of key personnel. It does not, however, provide direct insight into operational or financial performance.

Positives

• The grant of restricted stock rights and stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects and strategic direction.

Future Outlook

The equity grants, particularly the stock options with a future vesting schedule and expiration date, indicate a long-term incentive structure for the director, aligning his future performance with the company's stock appreciation.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and logistics sectors, where equity grants are commonly used to incentivize and retain key personnel, aligning their interests with long-term shareholder value creation. Cryoport operates in the specialized cold chain logistics for life sciences, an industry experiencing growth.

Comparison to Industry Standards

• Equity grants of this nature (restricted stock and stock options) are a common component of director compensation across various industries, including life sciences and logistics.
• The structure of vesting over time and an exercise price for options is standard practice to encourage long-term commitment and performance.
• Without specific peer compensation data, a direct quantitative comparison of the grant size to comparable companies in specialized cold chain logistics or broader biotech services is not feasible from this document alone.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value creation.

Next Steps

• Vesting of 1/12th of options monthly starting July 6, 2025.
• Full vesting of restricted stock rights on June 6, 2026.

Key Dates

Keywords

Cryoport, CYRX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership